Objective – studying species belonging to the causative agents of trichomoniasis of the genitourinary system in patients with sexually transmitted infections and immunodeficiency, assessing efficiency of their treatment. 77 patients with sexually transmitted infections and immunodeficiency were examined using the method of polymerase chain reaction in order to detect trichomonas species. 32 patients were given treatment and immune system indicators dynamics were determined. Trichomonas tenax was detected in 15.5%, Pentatrichomonas hominis – in 22%, Trichomonas vaginalis – in 4.1% of 77 examined patients. The method of combine treatment, providing for consecutive application of anti-protist substances of ornidazole and nifurotel with PROPES® taking smiltaniosly was effective to manage chronic trichomoniasis in 96.9% cases. Normalization of immune system took place. Trichomonias is a widespread disease in patients with sexually transmitted infections and immunodeficiency at the same time (41.6%). Application of the suggested original method allows us to achieve effective cure of chronic genital trichomoniasis caused by its various trichomonas species. Administration of PROPES® could be recommended as combined treatment of trichomoniasis on the background of immunodeficiency.Georgia has countrywide access to the genotypic and phenotypic drug susceptibility testing (gDST and pDST), however identification of susceptibility to the different anti-Tuberculosis (TB) drugs in different time period, not in all cases gives us opportunity to simultaneously know susceptibility to the all anti-TB drugs and to build an appropriate treatment regimens based on complete individual DST profile in timely manner. Initial TB treatment regimen prescribed based on gDST results not in all cases may be compliant with complete DST profile, which may be detected based on pDST results within eight weeks only. It’s important to know proportion of TB patients, who in period between gDST and pDST results are treated with regimens which is non-compliant with complete individual DST profile and how the use of these inappropriate treatment regimens may affect TB treatment outcome. The aim of the study was to assess compliance of anti-TB treatment regimens with complete DST profile in period between gDST and pDSTon study data discordance between Xpert MTB/RIF and culture tests were revealed. From all 7221 (85.3%) Xpert (MTB+) cases, only 5915 cases were culture positive too. All 400 (4.7%) patients with Xpert (MTB-) results were Culture positive. In 664 cases with Xpert (MTB+) results, Culture was negative. For successful outcomes, all efforts should be done to have the individual and complete DST profiles of all patients at initial stage of TB diagnosis. Otherwise, in case of delayed DST results anti-TB treatment for a certain period maybe inappropriate and can raise the risk of non-successful outcome.The purpose of the study is to examine in depth and analyze renal, hepatic and immune function indices in patients with Duchenne muscular dystrophy. We analyzed the follow up clinical and laboratory data of Duchenne muscular dystrophy in 32 patients. The patients underwent a standardized examination, involving studying the medical case history, general clinical data, determining Sheldon’s somatotype and the constitutional type, the detailed neurological status examination, testing a personality type, laboratory and instrumental examinations. Through the laboratory examination we determined the general blood test indicators, total serum protein levels, total cholesterol, the ALAT, ASAT, CPK levels, creatinine and urea blood levels, glomerular filtration rate (GFR), the immunogram indices (dynamic data (B-lymphocytes (CD19/CD45), %; T-lymphocytes (CD3/CD 45), %; T-helpers (CD3/CD45/CD4), %; T-suppressors (CD3/CD45/ CD8), %; CD4CD8 ratio; natural killer cells ratio, myositis profile (Mi-2, IgG antibodies (idiopaophy. Concurrently, we revealed the presence of a direct strong correlation between the Creatine phosphokinase level and the alanine aminotransferase level, which was equal to +0,86 (р less then 0,05) and the presence of a direct moderate correlation between the aspartate aminotransferase and the Creatine phosphokinase level which was equal to + 0.56 (р less then 0,05). We also found that the level of alkaline phosphatase was also significantly higher than the normal one in 69% of our patients. The patients with Duchenne muscular dystrophy had various multidirectional disorders of the immune status, impaired renal function (in particular, a decrease in serum creatinine concentration and reduced glomerular filtration rate), as well as the divergence of liver enzyme parameters (in particular, a significant increase in transaminase levels).The most common comorbidities in patients with rheumatic diseases include cardiovascular diseases (CVD), liver and biliary tract infection, lung diseases, amyloidosis, fractures of different localizations, malignant neoplasms, metabolic disorders and diabetes mellitus (DM). The aim of study was to investigate the clinical course of DM and rheumatoid arthritis (RS) in patients with RA using laboratory and instrumental research methods. Upadacitinib cell line There were examined 85 patients with RA who were treated in the rheumatology department of Ivano-Frankivsk Central City Clinical Hospital. The patients’ age ranged from 40 to 70 years. Endothelial dysfunction (ED) signs were observed in 76 (89.4%) patients. ED was diagnosed in all patients with RA, co-existent RS and DM. In the patients with RA and those with RA and co-existent RS, impaired EDVBA was detected. In the patients of Group II, the indicator of EDVBA (6.5±0.2%) was significantly lower as compared to the patients of Group I (8.8±0.3%) (р less then 0.05). The levels of both CRP and TNF-α, serving as non-specific inflammatory markers, were significantly higher (29.37±3.56 mg/l, p less then 0.01) in the patients with RS as compared to the patients with RA only (23.89±1.77 mg/l). A detailed study of the pathophysiological and immunological features of the clinical course of secondary RS will allow us to optimize its treatment schemes in patients with RA, reduce clinical and laboratory manifestation of RA and improve quality of life in such patients, especially those with a comorbidity.